期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 49, 期 6, 页码 668-673出版社
WILEY
DOI: 10.1177/0091270009336233
关键词
Chimeric natriuretic peptide; CD-NP; C-type natriuretic peptide; Dendroaspis natriuretic peptide
资金
- National Institutes of Health [R01 HL36634, P01 HL76611, R01 HL83231]
- Mayo Foundation
- Canadian Institutes of Health Research Clinical Research Initiative Fellowship
- Heart Failure Society of America
- American Society for Clinical Pharmacology and Therapeutics
CD-NP is a novel chimeric natriuretic peptide (NP) consisting of the 22-amino-acid (AA) human C-type natriuretic peptide (CNP), a venodilating peptide with limited renal actions and minimal effects on blood pressure, and the 15-AA C-terminus of Dendroaspis NP (DNP). The rationale for the design of CD-NP was to enhance the renal actions of CNP, the ligand for natriuretic peptide receptor-B, but without inducing excessive hypotension. Here we report the first-in-human studies for CD-NP, which represent the first successful clinical testing of a chimeric NP demonstrating in normal human volunteers that CD-NP possesses cyclic guanosine monophosphate-activating, natriuretic, and aldosterone-suppressing properties without inducing excessive hypotension, laying the foundation for additional studies on this first-in-class new cardiovascular therapeutic in human heart failure, which are now underway worldwide.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据